News | Stents Drug Eluting | November 01, 2016

First Clinical Data of Medtronic Drug-Filled Stent Show Positive Outcomes

RevElution Trial data at TCT highlight potential benefits of first-of-its-kind polymer-free technology with controlled and sustained drug delivery for rapid vessel healing

Medtronic, Drug-Filled Stent, DFS, RevElution trial, first clinical data, TCT 2016, Stephen Worthley

November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel Drug-Filled Stent (DFS) from the RevElution Trial at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, held Oct. 29-Nov. 3 in Washington, D.C. Also published simultaneously in the Journal of the American College of Cardiology (JACC): Cardiovascular Intervention, the polymer-free DFS met its primary endpoint of in-stent late lumen loss at nine months compared to a current-generation drug-eluting stent (DES), and also demonstrated positive clinical outcomes.

The RevElution trial enrolled 101 patients, with de novo coronary lesions 2.25-3.50 mm in diameter and length ≤ 27 mm, at 14 centers in three countries in two different 50-patient cohorts, measuring outcomes at nine months and 24 months via angiography, intravascular ultrasound and clinical assessment. The primary endpoint was angiographic in-stent late lumen loss at nine months compared with historical data from the zotarolimus-eluting stent (Resolute) as a control. In the first 50 patients included in the nine-month primary endpoint cohort, the DFS had in-stent late lumen loss of 0.26mm, which was non-inferior to the historical control (p<0.001). In addition, the DFS demonstrated low rates of target lesion failure (2.1 percent) and zero stent thrombosis at nine months.

Optical coherence tomography (OCT) data were reported from two cohorts of patients who were scheduled to receive OCT either at one and nine months (15 patients), or three and nine months (15 patients). In both groups, the DFS showed an early healing profile with the median strut coverage (new cell growth over stent struts) of 91.4 percent and 95.6 percent at one and three months, respectively, and low rates of malapposed struts at one month (0.3 percent) that decreased to 0 percent at nine months. At nine months, the median strut coverage increased to 99.1 percent with no cases of late-acquired stent malapposition.

"These early results demonstrate that the controlled and sustained elution of the polymer-free DFS show the potential for rapid healing without inflammation and positive clinical outcomes," said Stephen Worthley, M.D., professor at the Royal Adelaide Hospital in Adelaide, Australia and co-principal investigator of the DFS trial who presented the data at TCT. "In addition, we look forward to better understanding how this technology may potentially impact the duration of dual antiplatelet therapy in some patients."

Click to watch a video interview with Stephen Worthley at TCT 2015 "Drug-Filled Stents as an Alternative to Polymer Drug Carriers."

The DFS builds on the proven Continuous Sinusoid Technology (CST) platform and innovative CoreWire Technology. Introduced with the Resolute Integrity DES (drug-eluting stent), CST is a method of manufacturing that involves forming a single strand of wire into a sinusoidal wave to construct a stent, enabling a continuous range of motion, resulting in excellent deliverability and conformability to the vessel wall. CoreWire Technology — introduced with the next-generation Resolute Onyx DES (investigational in the United States) — allows the stent-forming wire to have multiple layers with a denser core metal surrounded by a cobalt alloy outer layer for thinner struts and greater deliverability, while offering enhanced radiopacity (i.e., visibility during the procedure) without compromising structural strength.

The DFS features a novel tri-layer wire design. The innermost layer is removed and becomes a lumen continuously coated with drug. The drug (sirolimus) is eluted from the inside of the stent through multiple laser-drilled holes on the abluminal side (outer surface) of the stent. The polymer-free design allows for controlled and sustained drug elution directly into the arterial wall without the adverse vascular effects associated with polymers, such as inflammation due to polymer degradation, flaking or hypersensitivity reactions.

For more information: www.crf.org/tct

Related Content

CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init